Boryung (formerly Boryung Pharmaceutical) announced on the 24th that it has signed a joint research and development contract with Oncocross, an artificial intelligence (AI) new drug venture, to expand the indication of Canav (component name Pimasartan). It did not disclose the amount of the contract.

The two companies are planning to discover new indications of Canav using Oncocross' AI platform 'RAPTOR AI'. RAPTOP AI is an AI new drug development platform that finds optimal indications of drugs. It is said that it can be used to explore new indications of new drugs under development or already approved drugs, or to derive combinations of combination drugs.

RAPTOR AI finds indications by comparing gene expression patterns based on patient and disease big data held by Oncocross. Compared to the traditional drug discovery method, it is said that fast results can be derived with high accuracy and low cost. Through RAPTOR AI, various new drug candidates, including treatments for sarcopenia, were discovered and clinical entry was achieved.

Copyright © SmartTimes. Prohibited from unauthorized reproduction and redistribution